Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
arcticnovartis

  • Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site
  • New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
  • First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas
/by
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
arcticnovartis

  • Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolio
  • C3 glomerulopathy (C3G) studies add to body of evidence of Fabhalta long-term safety and efficacy profile in native and post-transplant disease recurrence patients
  • V-INCEPTION analyses highlight Leqvio adherence and goal attainment data when initiated early in post-acute coronary syndrome patients
/by